Ranbaxy Laboratories and its new owner Japan’s Daiichi Sankyo, which now holds 63.92% of Ranbaxy’s equity share capital, reconstituted a new 10-member panel.

From the company’s earlier 15 member panel, the company retained only three members including former owner Malvinder Singh, COO Atul Sobti and Religare CEO & MD Sunil Godhwani.

The newly announced board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment during the last month (Nov 2008).

Daiichi Sankyo’s president and CEO Takashi Shoda, and Senior Executive Officer Tsutomu Une, have also been nominated in the board as directors.

Atul Sobti would continue in his role as the Chief Operating Officer.

The other directors include Anthony Wild, Partner, BOWS Pharmaceuticals AG; Rajesh Shah, Co-chairman and MD, Mukand Ltd; Sunil Godhwani, CEO and MD, Religare Enterprise Ltd; Akhiro Watanabe, Representative Director, GCA Savvian Group; and Balinder Singh Dhillon, an advocate.

Besides persisting in with his existing duties as CEO & MD, Malvinder Mohan Singh has been nominated ad the chairman of Ranbaxy.

Malvinder Singh has also been announced as a member of senior global management team of Daiichi Sankyo.

As part of the restructuring, 10 existing directors, which consist of Shivinder Mohan Singh, Brian Tempest, Gurcharan Das, Vivek Bharat Ram and Ramesh Adige have stepped down.